US2018100166A1PendingUtilityA1

Compositions and Methods for Enhancing Bioenergetic Status in Female Germ Cells

Assignee: MASSACHUSETTS GEN HOSPITALPriority: Jun 29, 2011Filed: Nov 17, 2017Published: Apr 12, 2018
Est. expiryJun 29, 2031(~4.9 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 15/08C07D 277/36A61K 35/28A61K 31/498A61K 35/14C12N 15/873A61K 31/4745A61K 35/54C07D 233/60A61K 35/51C07D 233/88C07D 213/50C07D 495/04C12N 2517/10C07D 277/64A61K 31/277C12N 2501/40C12N 5/0609A61K 31/137C07D 277/587C12N 5/0682A61K 31/352A61K 31/05
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods comprising bioenergetic agents for restoring the quality of aged oocytes, enhancing oogonial stem cells or improving derivatives thereof (e.g., cytoplasm or isolated mitochondria) for use in fertility-enhancing procedures, are described.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A composition comprising a mammalian oocyte, a mammalian oogonial stem cell (OSC), the progeny of a mammalian OSC or a mammalian preimplantation zygote, a CD38 inhibitor and a nicotinamide adenine dinucleotide (NAD precursor), wherein:
 the OSC is obtained from ovarian tissue, is an isolated non-embryonic stem cell, and is mitotically competent and expresses Vasa, Oct-4, Dazl and Stella and, optionally, a stage-specific embryonic antigen;   the CD38 inhibitor is a compound selected from the group consisting of apigenin, luteolin, tyrphostin-8, berberine and SRT-1720; and   the NAD precursor is a compound selected from the group consisting of nicotinamide mononucleotide, nicotinamide riboside or nicotinic acid; and   wherein the CD38 inhibitor and the NAD precursor are present in the composition in an amount effective to enhance the bioenergetic status of said oocyte, OSC, progeny of an OSC or preimplantation zygote in said composition.   
     
     
         2 . The composition of  claim 1 , further comprising a culture medium selected from the group consisting of cell culture medium, oocyte retrieval solution, oocyte washing solution, oocyte in vitro maturation medium, ovarian follicle in vitro maturation medium, oocyte in vitro fertilization medium, vitrification solution and cryopreservation solution. 
     
     
         3 . The composition of  claim 1 , wherein the NAD precursor is nicotinamide riboside. 
     
     
         4 . The composition of  claim 1 , wherein the NAD precursor is nicotinic acid. 
     
     
         5 . The composition of  claim 1 , wherein a mammalian OSC is cultured. 
     
     
         6 . The composition of  claim 1 , wherein the mammalian oocyte, or OSC, progeny of an OSC or preimplantation zygote is from a human female. 
     
     
         7 . The composition of  claim 6 , wherein the human female is selected from the group consisting of females of advanced maternal age, females suffering from oocyte-related infertility and females with low ovarian reserve. 
     
     
         8 . The composition of  claim 2 , wherein the CD38 inhibitor and the NAD precursor are present in the medium in an amount effective to increase the number of functional mitochondria in the mammalian oocyte, OSC, progeny of an OSC or preimplantation zygote cultured in said medium. 
     
     
         9 . The composition of  claim 2 , wherein the CD38 inhibitor and the NAD precursor are present in the medium in an amount effective to increase the mitochondrial energy of the mammalian oocyte, OSC, progeny of an OSC or preimplantation zygote cultured in said medium. 
     
     
         10 . The composition of  claim 2 , wherein the CD38 inhibitor and the NAD precursor are present in the medium in an amount effective to increase the cellular energy of the mammalian oocyte, OSC, progeny of an OSC or preimplantation zygote cultured in said medium. 
     
     
         11 . The composition of  claim 1 , wherein the CD38 inhibitor is present at a concentration≥25 μM. 
     
     
         12 . The composition of  claim 1 , wherein the NAD precursor is present at a concentration≥100 μM. 
     
     
         13 . The composition of  claim 2 , wherein the medium further comprises ovarian tissue, ovarian follicles, bone marrow, umbilical cord blood or peripheral blood. 
     
     
         14 . The composition of  claim 1 , wherein the mammalian OSC expresses a stage-specific embryonic antigen.

Join the waitlist — get patent alerts

Track US2018100166A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.